SCCVII Syngeneic Model Overview
The SCCVII syngeneic model is a murine squamous cell carcinoma system derived from C3H/He mice and is one of the most established preclinical models for studying head and neck squamous cell carcinoma (HNSCC) in an immunocompetent setting. Originally induced by chemical carcinogenesis, SCCVII exhibits aggressive, locally invasive growth, strong desmoplastic stroma, and moderate immunogenicity—features that closely parallel those of human head and neck squamous carcinomas.
When implanted subcutaneously, orthotopically (e.g., buccal or tongue region), or intramuscularly, SCCVII cells form highly reproducible, vascularized tumors with consistent kinetics. The model is extensively used to evaluate radiation sensitizers, immune checkpoint inhibitors, cytokine therapies, and combination regimens targeting the tumor microenvironment and local immune suppression.
Request a Custom Quote for SCCVII Syngeneic ModelBiological and Molecular Characteristics
The SCCVII cell line was derived from a spontaneous squamous cell carcinoma arising in a C3H/He mouse following chronic chemical exposure. The cells display epithelial morphology, forming nests and cords typical of keratinizing squamous tumors. SCCVII expresses cytokeratin and E-cadherin, confirming epithelial origin, and exhibits upregulation of pro-inflammatory and angiogenic mediators such as VEGF, IL-6, and TGF-beta.
Molecular profiling reveals activation of EGFR, PI3K-AKT, and STAT3 signaling pathways, which promote tumor proliferation, angiogenesis, and immune evasion. The tumor microenvironment contains infiltrating macrophages, myeloid-derived suppressor cells (MDSCs), and regulatory T cells (Tregs), contributing to an immunosuppressive milieu. These characteristics make SCCVII an excellent model for immuno-oncology, radiotherapy synergy, and T-cell infiltration studies.
| Parameter | Description |
|---|---|
| Host strain | C3H/He (female, 6–8 weeks) |
| Tumor origin | Chemically induced squamous cell carcinoma (mouse) |
| Histological type | Head and neck squamous cell carcinoma |
| Inoculation route | Subcutaneous, orthotopic (oral cavity), or intramuscular |
| Tumor take rate | >90% |
| Doubling time | Approximately 4–5 days in vivo |
| Metastatic potential | Moderate; regional lymph node involvement possible |
| Immunophenotype | Cytokeratin⁺, E-cadherin⁺, PD-L1⁺, EGFR⁺ |
| Common applications | Radiotherapy, immunotherapy, checkpoint blockade, tumor microenvironment research |
In Vivo Model Development and Tumorigenicity
SCCVII tumors are typically established by subcutaneous injection of tumor cells into the flank or by orthotopic implantation into the oral cavity of immunocompetent C3H/He mice. Subcutaneous models are ideal for monitoring tumor volume and evaluating systemic therapies, while orthotopic implantation more closely replicates the local invasiveness and immune suppression characteristic of human head and neck cancer. Tumors generally appear within 7–10 days and grow aggressively, allowing efficient evaluation of therapeutic response.
The SCCVII system is particularly valuable for radiotherapy and immunotherapy combination studies. Its moderate immunogenicity permits measurable immune activation following checkpoint blockade or cytokine treatment, while its radioresponsive nature allows for the investigation of radiation-induced immune modulation. The model’s reproducibility and translational relevance make it a cornerstone in head and neck oncology research.
Request a Custom Quote for SCCVII Syngeneic ModelHistopathology and Immunohistochemical Profile
Histopathological evaluation of SCCVII tumors reveals stratified squamous epithelial nests with keratin pearls, intercellular bridges, and infiltrative growth into surrounding connective tissue. The stroma is fibrotic and rich in inflammatory infiltrates, including macrophages and lymphocytes. Areas of necrosis, microvascular proliferation, and local invasion are common, reflecting high-grade squamous cell carcinoma morphology.
Immunohistochemical staining demonstrates strong expression of cytokeratin and E-cadherin, confirming epithelial differentiation. Ki-67 labeling indicates high proliferative activity, while CD31 staining reveals an extensive vascular network. PD-L1 is moderately expressed and upregulated in response to cytokine signaling or radiation exposure. F4/80 and CD11b staining identify macrophage and myeloid cell populations within the tumor stroma, whereas CD3 and CD8 highlight scattered T-cell infiltration. These histological and immune features closely mimic those of advanced human squamous carcinomas.
Preclinical Applications and Drug Response
The SCCVII syngeneic model is widely employed for evaluating immunotherapies, radiation sensitizers, and novel targeted agents in head and neck cancer research. It has been used to study PD-1/PD-L1 and CTLA-4 checkpoint blockade, radiation-induced immune enhancement, and T-cell infiltration dynamics. SCCVII tumors show measurable responsiveness to immune stimulation, cytokine therapy, and anti-angiogenic agents, particularly when combined with radiotherapy.
The model also serves as a platform for testing macrophage reprogramming strategies, EGFR inhibitors, and nanoparticle-based drug delivery systems. Because SCCVII tumors can be established orthotopically, they are particularly useful for examining tumor microenvironmental responses in mucosal and irradiated tissues. Its reproducibility, immune-competent host background, and similarity to human head and neck squamous carcinoma make SCCVII one of the most translationally relevant syngeneic models in oncology.
Request This Model
To request the SCCVII syngeneic model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.
Request a Custom Quote for SCCVII Syngeneic Model